Review of clinical radioimmunotherapy

Expert Review of Anticancer Therapy

Volumn 6, Issue 3, 2006, Pages 445-461

  Pohlman, Brad ^a   Sweetenham, John ^a   Macklis, Roger M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antibody; Crossfire; Non Hodgkin's lymphoma; Radioimmunotherapy; Radiopharmaceutical; Targeted therapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARMUSTINE; CD20 ANTIGEN; COPPER 67; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DYSPROSIUM; ETOPOSIDE; HOLMIUM; IBRITUMOMAB TIUXETAN; IODINE 131; LUTETIUM 177; MELPHALAN; MONOCLONAL ANTIBODY; PHOSPHORUS 32; PHOSPHORUS 33; PREDNISONE; RADIOACTIVE IODINE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; RITUXIMAB; STRONTIUM 89; TOSITUMOMAB; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE; YTTRIUM 90; ANTINEOPLASTIC AGENT; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; YTTRIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; BETA RADIATION; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DOSIMETRY; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDICATION; DRUG SPECIFICITY; DRUG TARGETING; FEVER; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; HYPOTHYROIDISM; MEDICAL RESEARCH; METHODOLOGY; MOUSE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; REVIEW; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME; ANTIBODY PRODUCTION; AUTOTRANSPLANTATION; IMMUNOLOGY; NEOPLASM; RADIOMETRY; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 33644911467     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.3.445     Document Type: Review

References (102)

1. Mach JP, Buchegger F, Pelegrin A et al. Progress in Radiolabeled Monoclonal Antibodies for Cancer Diagnosis and Potential For Therapy. Fortner JG, Rhoads JE (Eds). JB Lippencott, PA, USA (1989). Accomplishments in Cancer Research, 1989 Prize Year. p 222.
2. Macklis RM. Radithor and the era of mild radium therapy. JAMA 264(5), 614-618 (1990).
3. Hamilton JG, Soley MH. Studies in iodine metabolism by the use of a new radioactive isotope of iodine. Am. J. Physiol. 127, 557 (1939).
4. Frantz VK, Ball LP, Keston AS et al. Thyroid carcinoma with metastases studied with radioactive iodine. Ann. Surg. 119, 668 (1944).
5. Lattimer JC, Corwin LA, Stapleton J et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J. Nucl. Med. 3(1), 316 (1990).
6. Larson SM, Krenning EP. A pragmatic perspective on molecular targeted radionuclide therapy. J. Nucl. Med. 46(Suppl. 1), S1-S3 (2005).
7. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy. Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 59, 1274-1287 (2004).
8. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 46(Suppl. 1), S4-S12 (2005).
9. Macklis RM. How and why does radioimmunotherapy work? Int. J. Radiat. Oncol. Biol. Phys. 59(5), 1269-1271 (2004).
10. Sgouros G. Dosimetry of internal emitters. J. Nucl. Med. 46(Suppl. 1), S18-S27 (2005).
11. 2 block, and cell division. Radiat. Res. 124, 201-207 (1990).
12. Maxon HR, Thomas SR, Hertzberg VS et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N. Engl. J. Med. 309, 937 (1983).
13. 90Y-labeled antiferritin in hepatoma. Int. J. Radiat. Oncol. Biol. Phys. 14, 1033 (1987).
14. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective. Semin. Oncol. 30(Suppl. 4), 10-21 (2003).
15. Bardies M, Bardet S, Faivre-Chauvet A et al. Bispecific antibody and iodine 131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J. Nucl. Med. 37, 1853-1859 (1996).
16. Stickney DR, Gridley DS, Kirk GA et al. Enhancement of monoclonal antibody binding to melanoma with single dose radiation or hyperthermia. NCI Monogr. 3, 47-52 (1987).
17. 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 22(8), 1469-1479 (2004).
18. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20(10), 2453-2463 (2002).
19. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46(1 Suppl.), S115-S116 (2005).
20. Du Y, Honeychurch J, Cragg MS et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 103, 1485-1494 (2004).
21. Spierings D, McStay G, Saleh M et al. Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Science Mag. 310, 66-67 (2005).
22. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J. Nucl. Med. 4(4), 465-474 (2003).
23. Siegel JA, Yeldell D, Goldenberg DM et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J. Nucl. Med. 4 (4), 67-76 (2003).
24. Koral KF, Kaminski MS, Wahl RL. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J. Nucl. Med. 44, 1541-1543 (2003).
25. 90Y-ibritumomab tiuxetan (Zevalin). Semin. Oncol. 30(Suppl.), 6-10 (2003).
26. Griffith MH, Yorke ED, Wessels BW et al. Direct dose confirmation of quantitative autoradiography with microTLD measurements for RIT. J. Nucl. Med. 29, 795 (1988).
27. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J. Nucl. Med. 46(Suppl. 1), S99-S106 (2005).
28. Joiner MC, Marples B, Lambin P et al. Low-dose hypersensitivity: current status and possible mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 49, 379-389 (2001).
29. Wahl RL. Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J. Nucl. Med. 46(1Suppl.), S128-S140 (2005).
30. Yorke ED, Wessels BW, Bradley EW. Absorbed dose averages and dose heterogeneities in radioimmunotherapy. Antibody Immunoconjugates Radiopharm. 4, 623 (1991).
31. 90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J. Nucl. Med. 44(12), 2000-2018 (2003).
32. 131I-anti-B1 antibody: assessment of tumor dose-response. J. Nucl. Med. 44 (2), 260-268 (2003).
33. Order SE, Klein JL, Ettinger D et al. Use of isotopic immunoglobulin in therapy. Cancer Res. 40, S1011-S1013 (1980).
34. Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with yttrium-90. J. Nucl. Med. 26, 503-509 (1985).
35. Press OW, Eary JF, Appelbaum F et al. Radiolabeled-antibody therapy of B-cell lymphoma, with autologous bone marrow support. N. Engl. J. Med. 329, 1219-1224 (1993).
36. 131I) antiB1 (anti-CD20) antibody. N. Engl. J. Med. 329, 459-465, (1993).
37. O'Keefe TL, Williams GT, Davies SL et al. Mice carrying a CD20 gene disruption. Immunogenetics 48, 125-132 (1998).
38. Li H, Ayert LM, Lytton J et al. Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem.278, 42427-42434 (2003).
39. Shan D, Ledbetter JA, Press OW. Signaling events involved in antiCD20-induced apoptosis of malignant human B-cells. Cancer Immunol. Immunother. 48, 673-678 (2000).
40. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1998).
41. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15, 3266-3274 (1997).
42. Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101, 2507-2513 (2003).
43. Flieger D. Renoth S. Beier I et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in Cd-20 expressing lymphoma cell lines. Cell Immunol. 204, 55-63 (2000).
44. Golay J, Lazzari M, Facchinetti V et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98, 3383-3389 (2001).
45. Bellosillo B, Villamor N, Lopez-Guillermo A et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanisms involving the generation of reactive oxygen species. Blood 98, 2771-2777 (2001).
46. van der Kolk LE, Grillo-Lopez AJ, Bears JW et al. Complement activation plays a key role in the side effects of rituximab treatment. Br. J. Haematol. 115, 807-811 (2001).
47. Clynes RA, Towers TL, Presta LG et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
48. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized antiCD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 98, 754-758 (2002).
49. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26, 133-143 (2000).
50. Mounier N, Briere J, Giselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes Bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101, 4279-4284 (2003).
51. Selenko N, Majdic O, Jager U et al. Cross-priming of cytotoxic T-cells promoted by apoptosis-inducing tumor cell reactive antibodies? J. Clin. Immunol. 22, 124-130 (2002).
52. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97, 101-106 (2001).
53. Hainsworth JD, Litchy S, Burris HA III et al. Rituximab as first line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 4261-4267 (2002).
54. Witzig TE, Vukov AM, Habermann TM et al. Rituximab therapy for patients with newly diagnosed, advanced stage follicular grade 1 non-Hodgkin's lymphoma: a Phase II trial in the North Central Cancer Treatment Group. J. Clin. Oncol. 23, 1003-1108 (2005).
55. Czuczman MS, Weaver R, Alkuzweny B et al. Prolonged clinical and molecular remission in patients with low grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9 year follow-up. J. Clin. Oncol. 22, 4711-4716 (2004).
56. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
57. Pfreundschuh M, Truemper L, Gill D et al. First analysis of the completed Mabthera International (MinT) trial in young adults with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI = 0 and no bulky disease. American Society of Hematology 46th Annual Meeting and Exposition, San Diego, CA, USA. Blood 104(Suppl. 1) (2004) (Abstract 8).
58. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 105, 14171-14123 (2005).
59. Knox S, Goris M, Trisler K et al. Yttrium-90-labeled antiCD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2(3), 457-470 (1996).
60. + B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17(12), 3793-3803 (1999).
61. Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14(7), 1974-1981 (1996).
62. + B-cell lymphoma: long-term follow-up of a Phase I/II study. Blood 103 (12), 4429-4431 (2004).
63. Gordon LI, Witzig T, Molina A et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma. 5(2), 98-101 (2004).
64. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20(15), 3262-3269 (2002).
65. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood 99(12), 4336-4342(2002).
66. Schilder R, Molina A, Bartlett N et al. Follow-up results of a Phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother. Radiopharm. 19(4), 478-481 (2004).
67. Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14(7), 1974-1981 (1996).
68. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4), 1259-1266 (2000).
69. Vose JM, Wahl RL, Saleh M et al. Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 18(6), 1316-1323 (2000).
70. 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19(19), 3918-3928 (2001).
71. Horning SJ, Younes A, Jain V et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. 23(4), 712-719 (2004).
72. Davis TA, Kaminski MS, Leonard JP et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Research 10, 7792-7798 (2004).
73. Emmanouilides C, Murray JL, Vo K et al. Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma: results with second-line therapy. American Society of Hematology 45th Annual Meeting and Exposition. San Diego, CA, USA. Blood 102(Suppl. 1) (2003) (Abstract 4949).
74. Gregory SA, Leonard JP, Vose JM et al. Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,777 patients with low-grade, follicular, and transformed non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 6561).
75. Witzig TE, White CA, Gordon LI et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular or transformed non-Hodgkin's lymphoma. J. Clin. Oncol. 21(7), 1263-1270 (2003).
76. Gregory SA, Leonard JP, Knox SJ et al. The iodine 131I tositumomab therapeutic regimen: summary of safety in 995 patients with relapsed/ refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 6732).
77. 131 tositumomab. Blood 105(12), 4576-4582 (2005).
78. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352, 441-449 (2005).
79. 90Y) Ibritumomab tiuxetan (Zevalin®) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood 104 (2004) (Abstract 720).
80. Press OW, Unger JM, Braziel R et al. A Phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology group protocol S9911. Blood 102, 1606-1612 (2003).
81. Radford JA, Ketterer N, Sebban C et al. Ibritumomab tiuxetan (Zevalin®) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: interim analysis for safety of a multicentre Phase III trial. American Society of Hematology 46th Annual Meeting and Exposition, San Diego, CA, USA. Blood 102(Suppl. 1) (2003) (Abstract 408).
82. Kaminski MS, Radford JA, Gregory SA et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J. Clin. Oncol. 24, 212 (2005).
83. Morschhauser F, Huglo D, Martinelli G et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label Phase II trial. American Society of Hematology 46th Annual Meeting and Exposition, San Diego, CA. Blood 104(Suppl. 1) (2004) (Abstract 41).
84. Press OW, Eary JF, Gooley T et al. A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96, 2934-2942 (2000).
85. Vose JM, Bierman PJ, Enke C et al. Phase I trial of iodine-131-tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 461-467 (2005).
86. Nademanee A, Forman S, Molina A et al. A Phase I/II trial of high-dose yttrium-90-ibritumomab tiuxetan I combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin's lymphoma. Blood 106, 2896-2902 (2005).
87. 131I-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res. 50, S1039-S1042 (1990).
88. 131I-CC49 in colorectal cancer. Cancer 73(Suppl.), 1057-1066 (1994).
89. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin. Cancer Res. 2, 1811-1818 (1996).
90. DeNardo SJ, Kroger LA, Lamborn KR et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 80(Suppl.), 2583-2590 (1997).
91. Meredith RF, Alvarez RD, Partridge EE et al. Intraperitoneal radioimmunotherapy of ovarian cancer: a Phase I study. Cancer Biother. Radiopharm. 16, 305-315 (2001).
92. 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58, 972-975 (2004).
93. 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res. 47, 5672-5677 (1987).
94. Saga T, Sakahara H, Nakamoto Y et al. Enhancement of the therapeutic outcome of radioimmunotherapy by combination with whole-body mild hyperthermia. Eur. J. Cancer 37, 1429-1434. (2001).
95. Jhanwar YS, Difgi C. Current status of therapy of solid tumors. J. Nucl. Med. 46(Suppl. 1), S141-S150 (2005).
96. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J. Nucl. Med. 46(Suppl. 1), S199-S204 (2005).
97. Goldenberg DM, DeLand F, Kin E et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N. Engl. J. Med. 298, 1394-1396 (1978).
98. 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J. Clin. Oncol. 23(27), 6763-6770 (2005).
99. 90Y-DOTA-biotin. J. Nucl. Med. 41, 131-140 (2000).
100. Sharkey RM, McBride WJ, Karacay H et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 63, 354-363 (2003).
101. 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16, 227-235 (2001).
102. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10, 415-427 (2004).